In this issue:
Ovarian ablation or suppression for breast cancer: recurrence and survival
AI-based risk score for intermediate-term prediction of breast cancer
Real-world treatment of hormone receptor+ breast cancer after progression on CDK4/6 inhibitor
Trastuzumab brengitecan in advanced breast cancer and other solid tumours
SLNB for cN1 hormone receptor+, HER2– breast cancer and palpable adenopathy
Targeting homologous recombination deficiency in stage III breast cancer
Tailoring RT to nodal response in cT1–2N1 breast cancer on primary chemotherapy
Long-term outcomes and treatment response in early-stage ILC
Tucatinib combination maintenance prolongs PFS in HER2+ metastatic breast cancer
Durvalumab + neoadjuvant chemotherapy in early triple-negative breast cancer
Please login below to download this issue (PDF)